News
Vetter Expands its Footprint in Asia Pacific Region
Vetter, one of the global leaders in prefilled drug-delivery systems, announced the official opening of a new branch office in South Korea. The new office in Songdo is located within the biologics cluster which is often...
News
NeoGenomics Europe S.A. Opens its Doors in Rolle, Switzerland Laboratory Hosting Business Leaders, Dignitaries and Local Government Officials
NeoGenomics Inc , a leading global specialty oncology testing laboratory, opened the doors of its new Rolle, Switzerland facility on Wednesday, November 8th to bring its unique Pharma Services offering to the global research community. Rolle...
News
Apceth Biopharma Appoints a New Supervisory Board
Apceth Biopharma GmbH, a leading company developing the next generation of cell-based therapies, announced the appointment of a new Supervisory Board. The Supervisory Board will be responsible for advising and supporting the company on its corporate...
News
Priorclave Energy Efficient Autoclaves at Medica
Models from the popular Priorclave range of front loading autoclaves will be highlighted in Hall 3A – stand D06-6 at this year’s Medica * exhibition in Dusseldorf. The exhibition gives this British autoclave manufacturer Priorclave the...
News
Lonza Announces New Offering of Silensomes™ HLM for Drug Metabolism Studies
Lonza Walkersville announced its new offering of Silensomes™ Human Liver Microsomes (HLM) products – pooled human liver microsomes for in vitro cytochrome P450 (CYP) phenotyping. CYP phenotyping is a regulatory requirement for new drug candidates to...
News
Eisai to Present Latest Data at 10th Clinical Trials on Alzheimer’s Diesase
Eisai Co., Ltd. announced that the latest data on its oral dual orexin receptor antagonist lemborexant and its oral beta secretase cleaving enzyme (BACE) inhibitor elenbecestat(1) will be presented at the 10th Clinical Trials on Alzheimer's Disease (CTAD), taking...
News
SOTIO Completes Enrolment of Phase III VIABLE Study in Late Stage Prostate Cancer
SOTIO, a biotechnology company owned by the PPF Group, announced the enrolment of the last patient into the VIABLE study, a global Phase III clinical trial evaluating DCVAC/PCa in combination with docetaxel in patients with metastatic castration resistant prostate...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read